Teplizumab
Tzield (teplizumab) is an antibody pharmaceutical. Teplizumab was first approved as Tzield on 2022-11-17. It is used to treat type 1 diabetes mellitus in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Tzield
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Teplizumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Tzield | teplizumab-mzwv | Provention Bio | N-761183 RX | 2022-11-17 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tzield | Biologic Licensing Application | 2022-11-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 1 diabetes mellitus | EFO_0001359 | D003922 | E10 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 3 | 8 | 4 | — | 1 | 12 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | — | 1 | — | — | — | 1 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 1 | — | — | — | 1 |
| Islets of langerhans transplantation | D016381 | 1 | 1 | — | — | — | 1 | ||
| Homologous transplantation | D014184 | 1 | 1 | — | — | — | 1 | ||
| Experimental diabetes mellitus | D003921 | 1 | 1 | — | — | — | 1 | ||
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TEPLIZUMAB |
| INN | teplizumab |
| Description | Teplizumab (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 876387-05-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1743078 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06606 |
| UNII ID | S4M959U2IJ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 740 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more